Search
Selected Filter
Displaying 1–10 of 180 research results
-
FDA Authorizes Stem Cell Clinical Trial for RP in Los Angeles
Phase 1/2a human study will evaluate neural progenitors for preserving vision
-
AGTC Announces Development of Stargardt Disease Gene Therapy
Dual-vector delivery system designed to deliver the large ABCA4 gene
-
Iveric Bio’s Therapy Slows Retinal Degeneration in Phase 2b Trial for Dry AMD
Zimura inhibits a complement protein known as C5, a component of the immune system that, when overactive, can cause retinal degeneration.
-
ReNeuron Reports Interim Results for Eight Patients with RP in Phase 2a Trial for Stem Cell Therapy
The Foundation funded earlier lab studies that made the clinical trial possible.
-
FDA Approves New Wet AMD Treatment that can be Administered Every Three Months
Beovu from Novartis reduces treatment burden for wet AMD patients
-
AGTC Reports Promising Interim Results for XLRP and Achromatopsia Gene Therapy Trials
AGTC used Foundation’s My Retina Tracker registry to recruit patients for trials
-
Consortium Genetically Tests 40 Percent of People in Israel with IRDs
Patient benefits from genetic testing for IRDs include confirmation of their clinical diagnosis, identification of the disease inheritance pattern and risk for other family members, and determination of human studies for emerging therapies that may be appropriate for them.
-
The treatment focuses on the P23H mutation in the RHO gene, which is the most prevalent variant causing adRP in the US and affects approximately 2,500 people.
-
Allergan and Editas Begin Recruiting for CRISPR/Cas9 Clinical Trial for LCA10
The trial will be the first for a CRISPR/Cas9 therapy administered inside the human body.
-
The Foundation’s Contributions to Genetic Research Published in Peer-Reviewed Journal
The nonprofit has emerged as a driving force in genetic research and treatment development for inherited retinal diseases.
